Research programme: osteoporosis therapeutics - PharmaGAP/In Silico Pharma
Latest Information Update: 04 Dec 2009
Price :
$50 *
At a glance
- Originator In Silico Pharma; PharmaGap
- Class Peptides; Small molecules
- Mechanism of Action Gap junction modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 28 Apr 2004 Preclinical trials in Osteoporosis in Canada (unspecified route)
- 28 Apr 2004 Preclinical trials in Osteoporosis in Denmark (unspecified route)